~~<i id='B21352D2CB'><strike id='B21352D2CB'><tt id='B21352D2CB'><pre id='B21352D2CB'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：hotspot 2025-09-28 23:44:32 Page View：165

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biogen shutters digital health group, ends Apple study, in cost cutting move
Next article： In age of alternative facts, a scholarly course on calling out crap

leisure time

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Kaiser Permanente unions announce official strike date

AdobeYou’rereadingthewebeditionofHealthCareInc.,STAT’sweeklynewsletterfollowingtheflowofmoneythrough

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Did you have Obamacare on your GOP debate bingo card?

AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis. Signuphere toreceivethisnewsletterinyourinb